这一组疾病将脂质运输的生理过程与两项主要临床问题联系起来。其一是动脉粥样硬化性疾病,能够滞留于动脉壁的含载脂蛋白 B 颗粒持续暴露可促进该病发生。其二是与严重高甘油三酯血症相关的急性胰腺炎,尤其发生于乳糜微粒蓄积时。血管风险往往历经数十年逐渐形成,而胰腺炎风险可能在短时间内成为首要问题。识别何种风险占主导地位属于初始评估的一部分,而不应等到选药时才予以区分。
Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.European Heart Journal. 2020;41(1):111–188.
Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.European Heart Journal. 2025;46(42):4359–4378.
Borén J et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.European Heart Journal. 2020;41(24):2313–2330.
Ference BA et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.European Heart Journal. 2017;38(32):2459–2472.
Ginsberg HN et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society.European Heart Journal. 2021;42(47):4791–4806.
Newman CB et al. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline.The Journal of Clinical Endocrinology & Metabolism. 2020;105(12):3613–3682.
Nordestgaard BG et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.European Heart Journal. 2016;37(25):1944–1958.
Langlois MR et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.Clinical Chemistry. 2018;64(7):1006–1033.
Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.European Heart Journal. 2022;43(39):3925–3946.
Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.European Heart Journal. 2021;42(34):3227–3337.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.The Lancet. 2010;376(9753):1670–1681.
Cannon CP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.The New England Journal of Medicine. 2015;372(25):2387–2397.
Sabatine MS et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.The New England Journal of Medicine. 2017;376(18):1713–1722.
Nissen SE et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.The New England Journal of Medicine. 2023;388(15):1353–1364.
Ray KK et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.The New England Journal of Medicine. 2020;382(16):1507–1519.
Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.The New England Journal of Medicine. 2019;380(1):11–22.
Nordestgaard BG et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.European Heart Journal. 2013;34(45):3478–3490.